3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
2
Genitourinary
2
Breast
2
Sarcoma
1
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
96
Head and Neck Neoplasms
78
Carcinoma, Non-Small-Cell Lung
16
Oropharyngeal Neoplasms
13
Mouth Neoplasms
11
Carcinoma, Squamous Cell
11
Thyroid Carcinoma, Anaplastic
10
Neoplasm Metastasis
10
Thyroid Neoplasms
9
Salivary Gland Neoplasms
9
Recurrence
9
Hypopharyngeal Neoplasms
9
Carcinoma
9
Neoplasms
8
Nasopharyngeal Neoplasms
8
Nasopharyngeal Carcinoma
8
Melanoma
8
Laryngeal Neoplasms
8
Ovarian Neoplasms
7
Lung Neoplasms
7
Breast Neoplasms
7
Endometrial Neoplasms
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Colorectal Neoplasms
5
Small Cell Lung Carcinoma
4
Esophageal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Ovarian Epithelial
4
Tongue Neoplasms
3
Interventions
Trastuzumab
3
Docetaxel
3
Cisplatin
3
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tipifarnib
1
seribantumab
1
sargramostim
1
pertuzumab
1
lenvatinib
1
entinostat
1
Thalidomide
1
Taxes
1
Specimen Handling
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Immunohistochemistry
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Paclitaxel
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled